Tag Archive for: mHSPC
Radiotherapy in High-Burden Hormone-Sensitive Metastatic Prostate Cancer: Can It Be Useful?
/0 Comments/in Review/by MaxTruqap Shows Promise in Treating a Subtype of Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxFDA Accepts Darolutamide Plus ADT sNDA for mHSPC Treatment
/0 Comments/in Clinical Trial, FDA approvals, Metastatic, Phase 3/by MaxPSA Kinetics Predict Survival Outcomes in High-Volume Metastatic Prostate Cancer
/0 Comments/in Retrospective studies/by MaxDarolutamide Plus ADT and Docetaxel Extends Survival in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk in ARASENS Trial
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxDarolutamide Plus ADT: A Great Treatment Option for Metastatic Hormone-Sensitive Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025